Rapid Micro Biosystems RPID Switzerland — Revenue from Contract with Customer, Excluding Assessed Tax
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rapid Micro Biosystems in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax?
- Rapid Micro Biosystems (RPID) reported switzerland — revenue from contract with customer, excluding assessed tax of $1.37M in Q1 2026.
- How has Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax changed year-over-year?
- Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax decreased by 7.6% year-over-year, from $1.48M to $1.37M.
- What is the long-term trend for Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax?
- Over 4 years (2021 to 2025), Rapid Micro Biosystems's switzerland — revenue from contract with customer, excluding assessed tax has grown at a 8.7% compound annual growth rate (CAGR), from $4.31M to $6.02M.
- What does switzerland — revenue from contract with customer, excluding assessed tax mean?
- This metric represents the total revenue generated from contracts with customers specifically attributed to the Switzerland geographic segment, excluding any assessed taxes. It reflects the market penetration and commercial success of the company's automation solutions within the Swiss pharmaceutical and life sciences manufacturing sector. Monitoring this figure helps investors assess regional growth trends and the adoption rate of the company's technology in a key global hub for biologics and sterile injectable production.